AU2011300376A1 - Ingredients derived from Sphaeranthus indicus - Google Patents

Ingredients derived from Sphaeranthus indicus Download PDF

Info

Publication number
AU2011300376A1
AU2011300376A1 AU2011300376A AU2011300376A AU2011300376A1 AU 2011300376 A1 AU2011300376 A1 AU 2011300376A1 AU 2011300376 A AU2011300376 A AU 2011300376A AU 2011300376 A AU2011300376 A AU 2011300376A AU 2011300376 A1 AU2011300376 A1 AU 2011300376A1
Authority
AU
Australia
Prior art keywords
energy
extract
sphaeranthus indicus
mammal
derived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2011300376A
Other versions
AU2011300376B2 (en
Inventor
Venkata Krishna Raju Alluri
Kiran Bhupathiraju
Ganga Raju Gokaraju
Rama Raju Gokaraju
Venkata Kanaka Ranga Raju Gokaraju
Trimurtulu Golakoti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laila Nutraceuticals
Original Assignee
Laila Nutraceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laila Nutraceuticals filed Critical Laila Nutraceuticals
Publication of AU2011300376A1 publication Critical patent/AU2011300376A1/en
Application granted granted Critical
Publication of AU2011300376B2 publication Critical patent/AU2011300376B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L5/00Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/38Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention discloses herbal ingredients derived from Sphaeranthus indicus standardized to at least one frullanolide/eudesmanoid sesquiterpene compound and their compositions as natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a mammal. The invention further includes the use of ingredients and compositions for food ingredient formulations such as dietary supplement, food ingredient, beverage, snack or energy drink containing the above said herbal ingredient(s) for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal.

Description

WO 2012/032544 PCT/IN2011/000612 "SPHAERANTHUS INDICUS DERIVED INGREDIENTS AND THEIR COMPOSITIONS FOR ENHANCING PHYSICAL PERFORMANCE AND ENERGY LEVELS" FIELD OF INVENTION: The invention discloses a herbal ingredient selected from extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) as natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a mammal. The invention further relates to food ingredient formulations such as beverages, dietary ingredient formulation, snacks and energy drinks containing the above said herbal ingredient or its composition(s) for onset and steady maintenance of energy and mental alertness such as enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health. BACK GROUND OF THE INVENTION: Physical activity, such as exercise, particularly in the heat, places a demand on the body's carbohydrate stores, such as muscle glycogen, liver glycogen, and plasma glucose. Loss of water, redistribution and loss of electrolytes, and the depletion of endogenous carbohydrate reserves are primary causes of fatigue/tiredness that impairs one's work capacity. To maintain the body's physical capabilities, it is essential that water, electrolytes, carbohydrate, and other nutrients be provided in a timely and appropriate manner. Fluid replacement during physical activity has been shown to be effective in preventing dehydration and hyperthermia. The basic force and condition behind all activities of human life is the presence of energy. Energy is the vital principle needed to sustain life and it is required for every aspect of existence - every act uses energy - thinking, feeling, walking, eating, drinking, dreaming, breathing etc. Energy is felt and experienced upon its expenditure. The energy we experience immediately after eating (such as sweets), or the hype we get following the consumption of coffee is from the expenditure of energy from body's energy reserves, not WO 2012/032544 PCT/IN2011/000612 2 through its accumulation. Age, fatigue and stress make people feel deficient in energy. This drag in energy very often compromises body's mental alertness. Addressing body's energy demands properly, will increase one's efficiency at work place and in personal management. Dietary supplements are used by physically active people or weak people to increase their physical performance, physical fitness, improve their health, or reduce the potentially negative consequences of physical activity such as injury and chronic fatigue, or suppressed immune function. Many energy beverages, supplements and food ingredient formulations are presently available in the market. However, these are fully loaded with disaccharides, carbohydrate complexes, proteins, amino acids and vitamins along with numerous other agents. Many of these formulations act too quickly to give rise instant energy and not maintained over sustained period of time. Besides, these formulations tend to increase the blood glucose levels sharply and this is followed by their rapid depletion. This might some times lead to complications. Natural supplements, which improve the feeling of being energetic, general agility, endurance and mental alertness are thus in great demand. Studies are in process in many research groups across the globe to develop a superior product to address the above requirements. Therefore, the present invention addresses the existing need in the art by providing an ingredient(s) or composition(s) that provides energy and/or mental alertness. Thus, the present invention provides ingredient(s) and/or composition(s) capable of increasing energy levels for an extended period of time in a mammal to enhance both energy levels and mental alertness and thus solves these needs. SUMMARY OF INVENTION: In a major embodiment, the invention discloses a herbal ingredient selected from extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) for onset and steady maintenance of energy and mental alertness. The sphaeranthus derived ingredient and its compositions are useful for enhancing physical activity, physical fitness, mental WO 2012/032544 PCT/IN2011/000612 3 alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health in a mammal. In another embodiment, the invention relates to the preparation of dietary supplements, food ingredient formulations such as beverages, snacks and energy drinks containing the above said ingredient(s) or its composition(s) for onset and steady maintenance of energy and mental alertness. The formulation is useful for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health in a mammal. In a further embodiment, the extracts or fractions are standardized to 7 hydroxyfrullanolide, its analogs or their compositions for onset and steady maintenance of energy; mental alertness and for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in warm blooded animals in need thereof. In yet another embodiment, the invention provides compositions described above comprise at least one herbal ingredient selected from extract or fraction standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus in combination with at least one ingredient selected from extract(s), fraction(s), active compound(s), phytochemical(s), derived from plant(s), animal(s) or microorganisms with proven therapeutic health benefits; pharmaceutically or dietetically acceptable agents, active ingredients, vitamins, amino acids and minerals. In still another embodiment, one or more herbal ingredients derived from Sphaeranthus indicus or their compositions are useful for onset and steady maintenance of energy; mental alertness and for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in warm blooded animals in need thereof. In another embodiment, the invention provides a method of increasing natural energy to provide an onset and steady maintenance of energy and mental alertness in a mammal, wherein the method comprises supplementing or treating the said mammal with at least WO 2012/032544 PCT/IN2011/000612 4 one herbal ingredient selected from the extracts, fractions, compounds; extracts or fractions standardized to active compounds derived from Sphaeranthus indicus or their compositions. BRIEF DESCRIPTION OF FIGURES: Figure I: Figure shows Energy endurance capacity of LI12508 on swimming parameters. The bars represent resting time, moving slow time and moving fast times in seconds. Values are expressed as Mean + S.E.M, n=6. * p<0.05 and ** p<0.01 as compared to Control (ANOVA followed by Tukey's test) Figure II: Figure shows Percentage of energy endurance capacity of LI12508. The bars represent percentage resting time, moving slow time and moving fast times in seconds. Figure III: Figure shows Energy endurance capacity-Average distance travelled in mm. The bars represent average travelled by the control group and treatment group of animals supplemented with 100 mg/kg or 250 mg/kg body weight. Values are expressed as Mean ± S.E.M, n=6. ** p<0.01 as compared to Control (ANOVA followed by Tukey's test. Figure IV: Figure shows Energy Endurance capacity. The bars represent Average velocity exhibited by the control group and treatment group (100 mg/kg or 250 mg/kg body weight) of animals. Values are expressed as Mean ± S.E.M, n=6. * p<0.05 as compared to Control (ANOVA followed by Tukey's test). DETAILED DESCRIPTION OF INVENTION: For the purpose of this invention, the phrase 'herbal ingredient' OR 'herbal ingredients' OR 'said herbal ingredients' used in the specification and claims of the present invention refer to the extract(s), fraction(s); extract(s) or fraction(s) standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s). The phrase 'herbal ingredient' OR 'herbal ingredients' is used interchangeably through out the specification and the same may be appreciated as such by the person skilled in the art.
WO 2012/032544 PCT/IN2011/000612 5 The word 'composition' OR 'compositions' OR 'mixture' OR 'mixtures' determine the combination of one or more ingredients selected from extract(s), fraction(s) or compound(s) derived from Sphaeranthus indicus or other biologically active ingredients. The phrase 'biologically active ingredient' or 'biologically active ingredients' refers to other component(s) used for making compositions and selected from extract(s), fraction(s), active compound(s), phytochemical(s); powder(s) derived from plant(s), animal(s) or microorganisms with proven therapeutic health benefits; pharmaceutically or dietetically acceptable active ingredients, vitamins, amino acids or minerals. The phrase 'weak people' means those individuals who may or may not be suffering from a disease and the weakness can be of physical or mental. The word 'subject' OR 'subjects' means warm blooded animals, cold blooded animals, birds, horses, human beings or mammals of any sex. The inventors during their search for new anti-obese supplements have screened a large number of plant extracts for anti-adipogenesis activity using an in vitro assay in 3T3-L1 pre-adipocyte cells and found that extracts of Sphaeranthus indicus showed potent anti adipogenic activity. Subsequent studies have shown that Sphaeranthus indicus can potently ameliorate a wide range of metabolic protein markers directly related to obesity, diabetes, cardiovascular diseases and other metabolic disorders. The anti-obese efficacy of Sphaeranthus indicus was confirmed in an in vivo study in diet induced obesity and diet induced metabolic syndrome models of Sprague Dawley rats. The details of above experiments and the study results are described in inventor's previous Indian patent application and the corresponding PCT application 224/CHE/2009 filed 2 nd February, 2009; PCT/IN2010/000053 filed 1" February, 2010. In the present invention, a study was conducted using Sphaeranthus indicus extract standardized to 5% 7-hydroxyfrullanolide (LI12508) and a composition (LI12507F) containing Sphaeranthus indicus extract standardized to 5% 7-hydroxyfrullanolide in combination with Garcinia mangostana extract standardized to 10% a-mangostin (L180018) to assess their efficacy as an anti-obese supplement in a double blind placebo WO 2012/032544 PCT/IN2011/000612 6 controlled study in obese human subjects. Sixty obese subjects (27.6 % male; 72.4 % female; ages 22-50 years) were included in a randomized, double-blind, placebo controlled study of 56 days duration. The participants (BMI 30 to 40) were randomized into three groups; placebo, LI12508 group and LI12507F group. The participants received either 600 mg/day of L112508 and 800 mg of LI12507F formulation in two divided doses or two identical placebo capsules and all of them remained on a calorie-controlled diet (2000 Calories/day) and 30 min walking for 8 weeks. Various parameters including, physical, anthropomorphic, biochemical and questionnaire based evaluation including quality of life. The S. indicus extract (LI12508) and its formulation LI12507F provided significant reduction in body weight in both the treatment groups and also indicated promise for their potential use in controlling serum triglyceride levels. In addition, both LI12508 and L112507F also showed unexpectedly improved quality of life and improved energy, exercise ability and endurance in subjects supplemented with the treatments when compared the placebo treated group. This includes increased mobility, increased walking speed, increased walking distance, lack of fatigue, feeling untired, feeling light and active. Encouraged by this surprising result, the inventors evaluated the ability of the study products LI12508 and L112507F to enhance the ATP levels in a cellular model. The intracellular ATP level in the cells treated cells with L112508 and L112507F were measured by luminescence based ATP detection assay system, ATPlite (PerkinElmer Inc., Waltham, MA). Briefly, equal number of L6 Rat myocytes was plated in each well of a 96-well cell culture plate and cultured in DMEM supplemented with 10% FBS. The cells were treated with test samples (LI12508 and L112507F) at 50 pg/mL. Intracellular ATP level was quantitatively estimated from a standard curve plotted with luminescence units vs. known concentrations of ATP and the results compared with that obtained for the control treated sample as summarized in the table 1. Both the Sphaeranthus indicus extract standardized to 5% 7-HF (LI12508) and its composition (LI12507F) significantly increased the ATP levels in the rat myocyte cells, when compared to the control. The Energy Endurance potential of L112508 following oral administration was further evaluated in male and female Swiss albino mice. Swiss albino mice of 20 weeks old were selected and examined for health status and divided into three groups each consisting of 6 WO 2012/032544 PCT/IN2011/000612 7 animals (3 males and 3 females). The control group animals were treatedp.o with 0.5% of CMC and treatment groups were treated once a day with the test compound L112508 at 100 mg/kg or 250 mg/kg body weight for one week. On day 7, one hour after the treatment, the animals were tested for energy endurance with force swimming test using the SMART video tracking system (Panlab S.L.U). Resting time and its percentage, slow moving and its percentage, fast moving and its percentage, total path length of swimming and average velocity were analyzed using SMART video tracking software and the data is summarized in table 2. Based on the results obtained, there was a dose dependent decrease in mean resting time in animals supplemented with 100 or 250 mg/kg of the test substance, L112508. This mean reduction in resting time observed in treated groups is statistically significant when compared to control. In addition, the mean increase in slow swimming time, fast swimming time and average distance covered in both the treatment groups (100 mg/kg and 250 mg/kg) supplemented with LI12508 is also significant, when compared to control group as shown figures 1 to 3. Significant increase in average velocity was observed in animals treated with 250 mg/kg p.o as compared to control group as depicted in figure 4. The increase in mean slow swimming time and mean fast swimming time reveals that the animals treated with L112508 (100 mg/kg and 250 mg/kg) preferred to swim for a longer period of time instead of resting as observed in vehicle treated control animals. The increase in mean swimming velocity observed in 250 mg/kg L112508 treated animals, further support the increase in mean distance covered by the animals in the shorter period of time as compared to other two groups. This indicates the animals treated with L112508 were very active and energetic during 15 minutes forced swimming period and could tend to swim either slow or fast most of the time rather than resting when compared to control group treated with 0.5% CMC. The longer distance covered at higher velocity and shorter resting times observed in L112508 treated animals indicate that L112508 improves energy and endurance. Hence, it is obvious that supplementation of Sphaeranthus indicus extract can increase the energy levels and endurance potential. The forgoing demonstrates that Sphaeranthus indicus extract standardized to 5% 7 hydroxyfrullanolide (LI12508) and its composition in combination with Garcinia mangostana extract standardized to 10% a-mangostin (LI12507F) could be potent natural WO 2012/032544 PCT/IN2011/000612 8 supplements to provide an onset, steady maintenance of energy, physical endurance and mental alertness in humans and animals. Accordingly, in a major embodiment, the invention discloses a herbal ingredient selected from extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) for onset and steady maintenance of energy and mental alertness. The sphaeranthus derived ingredients and its compositions are useful for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better physical and mental health in a mammal. In another embodiment the invention discloses the composition consisting of Sphaeranthus indicus derived herbal ingredient in combination with at least one biologically active ingredient selected from extract of Garcinia mangostana fruit rind, Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamins, amino acids, taurine, an extract of Ginkgo biloba, Rhodiola and an extract of guarana, optionally in combination with an excipient, diluent or carrier as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof. In another embodiment, the invention relates to at least one Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to 7 hydroxyfrullanolide or its analogs or mixtures thereof as a natural energy enhancer to provide an enhanced physical or mental performance, onset and steady maintenance of energy and mental alertness in a mammal. In yet another embodiment, the invention relates to a composition comprising at least one herbal ingredient selected from extract or fraction standardized to at least one frullanolide/eudesmanoid sesquiterpene compound(s) derived from Sphaeranthus indicus or their composition(s) in combination with at least one ingredient selected from the extracts, fractions or compounds derived from Garcinia mangostana, further optionally containing at least one ingredient selected from excipient, diluent, vitamins or amino acids, as a natural energy enhancer for enhancing physical or mental performance, onset WO 2012/032544 PCT/IN2011/000612 9 and steady maintenance of energy enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in a mammal. In yet another embodiment, the invention provides a composition comprising at least one herbal ingredient selected from the extracts, fractions or compounds derived from Sphaeranthus indicus in combination with at least one ingredient selected from the extracts, fractions or compounds derived from Garcinia mangostana, optionally containing at least ingredient selected from excipient, diluent, vitamins or amino acids, as a natural energy enhancer for enhancing physical or mental performance, onset and steady maintenance of energy and mental alertness in a mammal. In another embodiment of the invention provides a composition comprising at least one herbal ingredient selected from the extracts or fractions standardized to at least one frullanolide/ eudesmanoid sesquiterpene compound such as 7-hydroxyfrullanolide (1) derived from Sphaeranthus indicus in combination with a Garcinia mangostana extract standardized to c-mangostin (2) or y-mangostin (3) and further optionally in combination with suitable excipients as a natural energy enhancer to provide an enhancing physical or mental performance, onset and steady maintenance of energy, mental alertness, for enhancing physical activity, physical fitness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in a mammal. Structures of 7-Hydroxyfrullanolide (1), a-mangostin (2) & y-mangostin (3) O OH Y %OH RO O HO O OH 1 0 2.R=CH3 3. R= H In still yet another embodiment of the invention provides a composition comprising at least one herbal ingredient selected from the extracts or fractions standardized to 5% 7- WO 2012/032544 PCT/IN2011/000612 10 hydroxyfrullanolide derived from Sphaeranthus indicus in combination with a Garcinia mangostana extract standardized to 10% a-mangostin and suitable excipients as a natural energy enhancer to provide an enhancing physical or mental performance, onset and steady maintenance of energy and mental alertness in a mammal. In another important embodiment, examples of improved physical performance include increased stamina and improved speed, strength, power, endurance, flexibility, agility, balance, focus coordination, reaction time, fatigue recovery and also increase of sex stamina. Examples of improved mental performance include improved sharpness, attention span, mental alertness, cognitive functions, mood elevation, and recovery or reduction of mental fatigue (e.g., following a high-intensity physical exercise). In another embodiment, the invention includes the preparation of dietary supplements, food ingredient formulations such as beverages, snacks and energy drinks containing the above said ingredient(s) or its composition(s) for enhancing physical activity, physical fitness, mental alertness, energy levels, stamina levels, circulatory health, blood vessel health or for better mental health in warm blooded animals in need thereof. In yet another embodiment the invention provides at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts or fractions standardized to active compound(s)/7-hydroxyfrullanolide or its analogs derived from Sphaeranthus indicus and compositions as natural enhancers of energy instantly, physical performance in warm blooded animals in need thereof. In another embodiment the extracts and/or fractions standardized to 7 hydroxyfrullanolide, its analogs or their compositions can be used for enhancing physical performance or energy levels in warm blooded animals. In yet another embodiment the invention provides compositions comprising biologically active ingredients in combination with one or more components selected from extract(s), fraction(s), active compound(s), phytochemical(s); powder(s) derived from plant(s), animal(s) or microorganisms with proven therapeutic health benefits; pharmaceutically or dietetically acceptable agents, active ingredients, vitamins, amino acids or minerals.
WO 2012/032544 PCT/IN2011/000612 11 In the other embodiment, the invention discloses composition containing Sphaeranthus indicus extract or fraction standardized to 7-hydroxyfrullanolide or its analogs in combination with at least one biologically active ingredient selected from an extract of Garcinia mangostana, Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamin B, vitamin C, Vitamin E, taurine, an extract of ginkgo biloba, Rhodiola and an extract of guarana. In another embodiment of the invention discloses the composition consisting of Sphaeranthus indicus derived herbal ingredient in combination with at least one biologically active ingredient selected from extract of Garcinia mangostana fruit rind, Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamins, amino acids, taurine, an extract of Ginkgo biloba, Rhodiola and an extract of guarana, optionally in combination with an excipient, diluent or carrier as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof. In another embodiment the invention discloses the compositions wherein the extract of Garcinia mangostana fruit rind is standardized to a-mangostin or y-mangostin or both and optionally in combination with at least one excipient/diluent as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof. In a further exemplary embodiment, the biologically active ingredients of the present invention for preparing the composition may further include one or more of the non limiting components such as vitamins selected from B vitamins, including thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, cyanocobalamin, choline and/or folic acid, including the reduced forms of folic acid such as but not limited to folinic acid, calcium folinate and methyltetrahydrofolate. The B-complex vitamins are also water soluble vitamins that aid the breakdown of carbohydrates into glucose to provide energy for the body, the breakdown of fats and proteins to aid the normal functioning of the nervous system, and muscle tone in the stomach and intestinal tract. Particular forms of B WO 2012/032544 PCT/IN2011/000612 12 vitamins in the composition may include d-Calcium pantothenate, niacinamide, pyridoxine hydrochloride, and thiamine mononitrate; or amino acids. In another embodiment the Sphaeranthus indicus derived herbal ingredient selected from the extracts or fractions standardized to 7-hydroxyfrullanolide or its analogs or mixtures thereof and/or their composition(s) increases circulation, metabolism efficiency, regulates neurotransmitters and boosts oxygen levels in the brain. Benefits of enhanced circulation in the brain include improved short and long term memory, increased reaction time and improved mental clarity. In yet another embodiment the said herbal ingredients or their composition(s) are useful for enhancing energy levels, mental alertness, stamina levels, circulatory health and blood vessel health as well as for providing nutritional support. It can also be used as an energy booster for patients in need thereof, e.g., cancer patients or AIDS patients. Moreover, it is useful for enhancing athletic performance in both humans and animals, e.g., horses. In another embodiment the said herbal ingredients and/or their composition(s) can be taken e.g. by performance athletes, those engaged in endurance and multi-discipline sports, aged and sick persons in order to increase mental and physical efficiency and to repress susceptibility to illnesses, such as cold, bacterial and viral infections, in a natural manner. The present ingredients and compositions may be formulated as a "fitness drink" that can be taken with breakfast or in the form of a concentrate from which such a drink can be regularly used. In another embodiment 7-hydroxyfrullanolide or its analogs obtained naturally, synthesized or semi-synthesized can be useful for enhancing physical or mental performance. In another embodiment one or more of the analogs of 7-hydroxyfrullanolide that can be used for preparing compositions comprise of frullanolides; lla,13-dihydro-3a,7a dihydroxy-4,5-epoxy-6p,7-eudesmanolide; la,13-dihydro-7a-acetoxy-3p-hydroxy-6p,7 eudesm-4-enolide; 3-keto-p-eudesmol; l la,13-dihydro-3a,7a-dihydroxyeudesm-4-en 6a, 1 2-olide; 11 a, 13-dihydro-3a,7a-dihydroxyfrullanolide; l la, 1 3-dihydro-7a, 13- WO 2012/032544 PCT/IN2011/000612 13 dihydroxyfrullanolide; 11 a, 13-dihydro-7a-hydroxy-13-methaoxyfrullanolide; 2a,7a dihydroxy-4-en-11,13-dihydroeudesm-6,12-olide; 2a-hydroxycostic acid; 3-keto-7a hydroxyeudesm-4-en-6,12-olide (cryptomeridiol); 4-epicryptomeridiol; sphaeranthanolide; 2a-hydroxysphaerantholide; 2a-acetoxysphaerantholide; 2a,7a dihydroxysphaerantholide; 2a-acetoxy-7a-hydroxysphaerantholide and 2a-acetoxy-5a hydroxyisosphaerantholide. The concentration of Sphaeranthus indicus derived 7-hydroxyfrullanolide or frullanolide/ eudesmanoid sesquiterpene compounds in the present invention individually or together varies in the range of 0.01% to 99.99%. The composition wherein, the concentration of Garcinia mangostana fruit rind extract, a mangostin and y-mangostin individually or jointly varies from 0.01% to 99.99%. In another embodiment the herbal ingredient(s) or composition(s) of the present invention are useful to improve aerobic performance and capacity by influencing lactic acid metabolism and reducing fatigue as well as for alleviation of one or more of the biological energy markers including but not limited to ATP levels/production; Nitric Oxide levels, NADH balance, leptin levels, adipocytes derived peptide In another embodiment the herbal ingredient(s) can further be combined with one or more biological active ingredients comprising anti-diabetic, anti-hyperlipidemic, anti-obesity, anti-hypertensive, anti-platelet aggregation, anti-infective, anti-atherosclerotic, anti inflammatory, anti-oxidant and bio-enhancing activity. In a further exemplary embodiment, the composition may contain an effervescent. As is understood, an effervescent is an agent comprising one or more compounds which, act individually or together, evolve a gas on contact with water. The gas evolved is generally oxygen or, most commonly, carbon dioxide. Preferred effervescent agents comprise an acid component and a base component that react in the presence of water to generate carbon dioxide gas. The acid component can comprise one or more acids and the base component can comprise one or more bases. Preferably, the base component comprises an alkali metal or alkaline earth metal carbonate or bicarbonate and the acid component WO 2012/032544 PCT/IN2011/000612 14 comprises an aliphatic carboxylic acid. Non-limiting examples of suitable bases for use in a base component include carbonate salts (e.g., calcium carbonate), bicarbonate salts (e.g., sodium bicarbonate), sesquicarbonate salts, and mixtures thereof. Sodium bicarbonate is a preferred base. Non-limiting examples of suitable acids for use in an acid component include citric acid, lactic acid, glutaric acid, phosphoric acid, acetic acid, tartaric acid, malic acid, fumaric acid, adipic acid, succinic acid, oxaloacetate, acid anhydrides of such acids, acid salts of such acids, and mixtures thereof. Citric acid is a preferred acid. In a further exemplary embodiment, the composition may contain sweeteners. Preferred sweeteners for use in the present invention are sugars and sugar alcohols such as sucrose, fructose, dextrose, maltose, lactose, high fructose corn syrup solids, invert sugar, sugar alcohols, including sorbitol, as well as mixtures of these sugars and sugar alcohols. In order to deliver lower levels of solids per dosage, it may be preferred to use a higher intensity sweetener with the sugar or sugar alcohol. These higher intensity sweeteners include saccharin, cyclamates, acesulfame K, L-aspartyl-L-phenylalanine lower alkyl ester sweeteners (e.g., aspartame); L-aspartyl-D-alanine amides; L-aspartyl-D-serine amides; L-aspartyl-L- 1 -hydroxymethylalkaneamide sweeteners; L-aspartyl- 1 hydroxyethyalkaneamide sweeteners; and L-aspartyl-D-phenylglycine ester and amide sweeteners. Further sweeteners contemplated for use with the compositions disclosed herein include sweeteners derived from stevia, sweeteners derived from momordica grosvenorii, and sweeteners derived from mogrosides. A particularly preferred sweetener system is a combination of sucralose with acesulfame K and corn syrup solids. In another exemplary embodiment, the composition may be dissolved in water or in other liquids suitable for human consumption. In another embodiment of the invention the various suitable solvents that can be used for preparing the extracts and fractions or extracting or fractionating the herbs such as Sphaeranthus indicus, Garcinia mangostana include but not limited to Cl-C5 alcohols, like ethanol, methanol; water and mixtures thereof; Cl -C7 hydrocarbons such as hexane; esters like ethyl acetate and the like and mixtures thereof.
WO 2012/032544 PCT/IN2011/000612 15 In another embodiment, the ingredients and compositions of the present invention may be formulated in dry form, liquid form, food product, dietary supplement or any suitable form such as tablet, a capsule or a soft chew. In another embodiment the herbal ingredient(s) or composition(s) can be delivered in the form of controlled release tablets, using controlled release polymer-based coatings by the techniques including nanotechnology, microencapsulation, colloidal carrier systems and other drug delivery systems. In another embodiment of the invention provides herbal ingredient(s) or their compositions nutritional/dietary supplements can be contemplated/made in the dosage form of healthy foods, or food for specified health uses such as solid food like chocolate or nutritional bars, semisolid food like cream or jam, or gel and also beverage and the like, such as refreshing beverage, lactic acid bacteria beverage, drop, candy, chewing gum, gummy candy, yoghurt, ice cream, pudding, soft adzuki bean jelly, jelly, cookie, tea, soft drink, juice, milk, coffee, cereal, snack bar and the like. The flavorant(s) that may be included in the composition are not relevant to the inventive concepts disclosed herein, and those skilled in the art are familiar with the wide range of flavorants available. Therefore, any suitable flavorant or combination of flavorants, natural and/or artificial, is within the contemplated scope of the present disclosure. In another exemplary embodiment, the composition may further include food colorants to improve the visual appearance of a drink prepared with the composition. The flavoring agent or agents may provide a fruit flavor, cola flavor, vanilla flavor, or a chocolate flavor, by way of example and not by way of limitation. Sweeteners, natural or synthetic, such as sucrose, sucralose, aspartame, and/or acesulfame potassium, neotame, polydextrose, glycerin, sorbitol, and xylitol, may be used, by way of example and not by way of limitation. Coloring agents may be added. Agents such as citric acid, fumaric acid, adipic acid, tartaric acid, and in some instances lactic acid may be added to adjust for tartness.
WO 2012/032544 PCT/IN2011/000612 16 Additional ingredients in the form of analgesics (e.g. aspirin), mild stimulants other than caffeine, which is mentioned above (e.g. green tea), or relaxants (e.g. melatonin), may be added in specialized product applications. In other embodiment, the herbal ingredients and composition of this invention are useful in treating mitochondrial deficiencies in both humans and animals. It also can be used for enhancing or maintaining physical or mental performance, reducing infection in physically stressed athletes or non-athletes from intense physical exercises. Moreover, it can be an activator of Sirtuin. In another exemplary embodiment the biologically acceptable ingredients or compositions can further be combined with one or more pharmaceutically or dietetically acceptable excipients, carriers and diluents, comprising glucose, fructose, sucrose, maltose, yellow dextrin, white dextrin, aerosil, microcrystalline cellulose, calcium stearate, magnesium stearate, sorbitol, stevioside, corn syrup, lactose, citric acid, tartaric acid, malic acid, succinic acid, lactic acid, L-ascorbic acid, dl-alpha-tocopherol, glycerin, propylene glycol, glycerin fatty ester, poly glycerin fatty ester, sucrose fatty ester, sorbitan fatty ester, propylene glycol fatty ester, acacia, carrageenan, casein, gelatin, pectin, agar, vitamin B group, nicotinamide, calcium pantothenate, amino acids, calcium salts, pigments, flavors, preservatives, distilled water, saline, aqueous glucose solution, alcohol, propylene glycol and polyethylene glycol, various animal and vegetable oils, white soft paraffin, paraffin and wax. In still another embodiment, the invention features a method for enhancing physical or mental performance, steady maintenance of energy, physical endurance and mental alertness in humans and animals, wherein the method comprises administering to a subject in need thereof an effective amount of at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts or fractions standardized to active compound(s)/7-hydroxyfrullanolide derived from Sphaeranthus indicus and compositions thereof. Examples of improved physical performance include increased stamina and improved speed, strength, power, endurance, flexibility, agility, balance, focus coordination, reaction time, fatigue recovery and also increase of sex stamina. Examples WO 2012/032544 PCT/IN2011/000612 17 of improved mental performance include improved sharpness, attention span, mental alertness, cognitive functions, mood elevation, and recovery or reduction of mental fatigue (e.g., following a high-intensity physical exercise). By properly administrating the ingredient or composition, a subject's physical or mental performance can be greatly enhanced without deleterious side effects. In still another embodiment, the invention features use of at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts or fractions standardized to active compound(s)/7-hydroxyfrullanolide derived from Sphaeranthus indicus and compositions thereof to enhance physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal or humans or animals. In still another embodiment of the invention, use of at least one herbal ingredient selected from the extract(s), fraction(s), compound(s), extracts and fractions standardized to active compound(s)/7-hydroxyfrullanolide derived from Sphaeranthus indicus and compositions thereof for the preparation of a medicament useful for enhancing physical or mental performance, steady maintenance of energy, physical endurance and mental alertness in humans and animals. Those of ordinary skill in the art will appreciate that changes could be made to the embodiments described above without departing from the broad inventive concept thereof. It is understood, therefore, that this invention is not limited to the particular embodiments or examples disclosed, but is intended to cover modifications within the objectives and scope of the present invention as defined in the specification. Example 1 Sphaeranthus indicus methanol extract (L112500): Sphaeranthus indicus flower heads (1 kg) were taken in a round bottom flask and extracted with methanol (8 L) at 60 - 65*C temperature for 2 h. The extract was filtered and the spent raw material was re-extracted twice with methanol (2 x 6 L) under similar conditions. The combined extract was fine filtered and concentrated over a climbing film evaporator to obtain a residue (110 g). The WO 2012/032544 PCT/IN2011/000612 18 methanol extract (LI12500) showed 11% of 7-hydroxyfrullanolide by HPLC method of analysis. Sphaeranthus indicus methanol extract standardized to 5% 7-hydroxyfrullanolide Sphaeranthus indicus methanol extract containing 7-hydroxyfrullanolide as obtained above was diluted with microcrystalline cellulose and magnesium strearate along with 2% by weight of aerosil to obtain Sphaeranthus indicus powdered methanol extract standardized to 5% 7-hydroxyfrullanolide (LI12508). Example 2 Sphaeranthus indicus ethanol extract: Sphaeranthus indicus flower heads (1 kg) were taken in a RB flask and extracted with ethanol (8 L) at 60- 65*C temperature for 2 h. The extract was filtered and the spent raw material was re-extracted twice with ethanol (2 x 6 L) under similar conditions. The combined extract was fine filtered and concentrated over a climbing film evaporator to obtain a residue (98 g). The ethanol extract showed 12% of 7-hydroxyfrullanolide by HPLC method of analysis. Example 3 Garcinia mangostana rind methanol extract (L180013): Shade dried fruit rind (lKg) of Garcinia mangostana was pulverized to coarse powder, and extracted with 90% methanol (5L) for 2 hrs at 60-65'C. The solvent was separated from the raw material by filtration. Extraction process was repeated three times using 90% methanol (2x3 L & 1x2 L). The combined extracts were fine filtered and concentrated under reduced pressure and allowed to precipitate at ambient temperature. The solid separated was filtered to give a dry powder (150 g, a-mangostin: 21% and y-mangostin: 2.5%). Example 4 Garcinia mangostana methanol extract standardized to 10% a-mangostin: Garcinia mangostana methanol extract containing a-mangostin as obtained above (example 3) was diluted with microcrystalline cellulose and magnesium strearate along with 2% aerosil to obtain Garcinia mangostana methanol extract standardized to 10% a mangostin (L180018).
WO 2012/032544 PCT/IN2011/000612 19 Example 5 Garcinia mangostana rind ethanol extract: Shade dried fruit rind (1Kg) of Garcinia mangostana was pulverized to coarse powder, and extracted with 90% ethanol (5L) for 2 hrs at 60-65*C. The solvent was separated from the raw material by filtration. Extraction process was repeated thrice using 90% ethanol (2x3 L & 1x2 L). The combined extracts were fine filtered and concentrated under reduced pressure and allowed to precipitate at ambient temperature. The solid separated was filtered to give ethanol extract as a dry powder (136 g, a-Mangostin: 22%). Example 6 Composition L112506F: The composition LI12506F was prepared by combining the methanol extract of Sphaeranthus indicus (LI12500) and 90% methanol extract of Garcinia mangostana (L180013), both as prepared above, in the ratio of 3:1. Example 7 Formulation LI12507F (Merastin*): The Sphaeranthus indicus powder extract standardized to minimum 5% 7-hydroxyfrullanolide (LI12508) and Garcinia mangostana methanol extract standardized to 10% a-mangostin (L180018) as prepared above were combined at 3 : 1 ratio and properly blended to obtain LI12507F. Example 8 Composition L112517F: Composition LI 12517F was prepared by mixing unit doses of the following components: One part of Sphaeranthus indicus ethanol extract (1 g) and Three parts of Garcinia mangostana 90% ethanol extract (3 g). Example 9 A study was conducted using Sphaeranthus indicus extract standardized to 5% 7 hydroxyfrullanolide (LI12508) and a composition containing Sphaeranthus indicus extract standardized to 5% 7-hydroxyfrullanolide in combination with Garcinia mangostana extract standardized to 10% a-mangostin (LII 2507F) to assess their efficacy as an anti-obese supplement in a double blind placebo controlled study in obese human subjects. Sixty obese subjects (27.6 % male; 72.4 % female; ages 22-50 years) were WO 2012/032544 PCT/IN2011/000612 20 included in a randomized, double-blind, placebo-controlled study of 56 days duration. The participants (BMI 30 to 40) were randomized into three groups; placebo, L112508 group and LI12507F group. The participants received either 600 mg/day of LI12508 and 800 mg of LI12507F formulation in two divided doses or two identical placebo capsules and all of them remained on a calorie-controlled diet (2000 Calories/day) and 30 min walking for 8 weeks. Various parameters including, physical, anthropomorphic, biochemical and questionnaire based evaluation including quality of life have been studied. The S. indicus extract (LI12508) and its formulation LI12507F provided significant reduction in body weight in both the treatment groups and also indicated promise for their potential use in controlling serum triglyceride levels. Impact of Weight on Quality of Life Questionnaire-Lite Version (IWQOL-Lite) including subjects feedback was administered to all the subjects at each evaluation point including days 0, 14, 28 and 56 was assessed. Subjects expressed improvement in various parameters including increased mobility, increased walking speed, increased walking distance and time, feeling untired, feeling light and active. Number of subjects expressed such improvement in physical ability and endurance was more in supplement groups compared to placebo group. Both L112508 and L112507F also showed unexpectedly improved quality of life and improved energy, exercise ability and endurance in subjects supplemented with the treatments when compared the placebo treated group. This includes increased mobility, increased walking speed, increased walking distance, lack of fatigue, feeling untired, feeling light and active. Example 10 Intracellular ATP level in the cells treated cells with LI12508 and L112507F were measured by luminescence based ATP detection assay system, ATPlite (PerkinElmer Inc., Waltham, MA). Briefly, equal number of L6 Rat myocytes was plated in each well of a 96-well cell culture plate and cultured in DMEM supplemented with 10% FBS. The cells were treated with different concentrations of test samples (LI12508 and ,112507F) for 4h and thereafter, to each well 50 ul of cell lysis buffer were added. The vehicle control culture wells received 0.2% DMSO (v/v). Finally, 50 ul of substrate solution was WO 2012/032544 PCT/IN2011/000612 21 added to each well and incubated at room temperature for 5 min on plate shaker. After 10 minutes of dark adaptation, the luminescence was read in a luminometer (Modulus Multimode Reader, Turner Biosystems Inc., Sunnyvale, CA). A serial dilution of an ATP standard solution ranging from 1x10- 5 M to blank was applied to the assay plate. Intracellular ATP level was quantitatively estimated from a standard curve plotted with luminescence units vs. known concentrations of ATP. Table 1 Dose ATP S. No Test Product Code pg/mL Concentration 1 Control - - 2.808 2 S. indicus 5% extract L112508 50 3.313 3 S. indicus composition L112507F 50 6.119 Example 11: Evaluation of Energy Endurance Capacity of herbal extract in Swiss albino mice: Eighteen Swiss albino mice of 20 weeks old were selected and examined for health status and acclimatized for one week before initiation of the study. The animals were randomly divided into three groups each consisting of 6 animals (3 males and 3 females) corresponding to two doses (100 and 250mg/kg body weight) of test substance L112508 and vehicle control. The animals were treated orally with allocated test substances or vehicle daily for 1 week. Swimming exercise (15 min) was initiated after 1 hr of treatment and continued daily for 7 days. Mice were allowed to swim with supporting constant loads (lead fish sinkers, attached to the tail) corresponding to 10% of their body weight, in a acrylic tank filled with water. On day 7 th, this swimming exercise for 15 min was tracked using the SMART video tracking system (Panlab S.L.U). Swimming time or resting time, Distance travelled and velocity of swimming was measured using the tracking software. Resting time and its percentage, moving slow and its percentage, moving fast and its percentage, total path length of swimming and average velocity were analyzed using SMART video tracking software and the data is summarized in table 2. There was a significant decrease in mean resting time and a significant increase in mean slow swimming time, mean fast swimming time and average distance covered in both 100 mg/kg and 250 mg/kg of L112508 treated group animals when compared to control treated animal group as summarized in the figures 1 to 2. Moreover, animals treated with WO 2012/032544 PCT/IN2011/000612 22 250 mg/kg p.o showed a significant increase in average velocity as compared to control group as depicted in figure 4. Table 2 EnerW Endurance Potential of LI12508 on Forced Swimming Test Parameters Paramete Restin Movin Movin Avera Resting Movin Movin rs Distance Timei g g Slow g Fast ge Tieg Slow g Fast Test (cm) Time Time Time Velocit (e)(%) (%) Article (Sec) (%) (See) (Sec) y 39588.39 662.63 73.57 192.74 21.40 45.29 111.40 CMC 5.03+ (Control) 1.44 5247.84 36.94 4.10 25.99 2.89 12.96 6.72 L112508 48345.11 64.83 27.87 116.27 574.63* 245.57* 7.30 100 ** * * 64.09*+ 0.71 mg/kg 3 2.90 2.33 5.36 2.71 31.56 19.48 2549.01 57160.52 125.96 LI12508 565.71* 62.80 252.40* 28.02 82.71* 250 * * + * 1.42 mg/kg + 2.75 1.65 6 4810.60 6.39 24.78 14.82 12.83 Values are expressed as Mean ± S.E.M, n=6. * p<0.05, **p<0.01 as compared to CMC control (ANOVA followed by Tukey's Test)

Claims (9)

1. A Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
2. A composition comprising at least one Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound in combination with at least one biologically active ingredient selected from extract of Garcinia mangostana fruit rind, Osmium basilicum, Zingiber officinalis, Tribulus terrestris, vitamins, amino acids, taurine, an extract of Ginkgo biloba, Rhodiola and an extract of guarana, optionally containing an excipient, diluent or carrier as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
3. A composition comprising at least one Sphaeranthus indicus derived herbal ingredient selected from the extract and fraction standardized to at least one frullanolide/eudesmanoid sesquiterpene compound in combination with an extract of Garcinia mangostana fruit rind standardized to a-mangostin or y-mangostin or both and at least one excipient/diluent as a natural energy enhancer to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof.
4. The Sphaeranthus indicus derived ingredient according to claims 1 to 3, wherein the compound for standardization is selected from the group consisting of 7 hydroxyfrullanolide; 11 a, 13-dihydro-3a,7a-dihydroxy-4,5-epoxy-6p,7 eudesmanolide; 11a,13-dihydro-7a-acetoxy-3p-hydroxy-6p,7-eudesm-4-enolide; 3-keto-p-eudesmol; la,13-dihydro-3a,7a-dihydroxyeudesm-4-en-6a,12-olide; 11a,13-dihydro-3a,7a-dihydroxyfrullanolide; 11a,13-dihydro-7a,13 dihydroxyfrullanolide; 11a,13-dihydro-7a-hydroxy-13-methaoxyfrullanolide; WO 2012/032544 PCT/IN2011/000612 24 2a,7a-dihydroxy-4-en-11,13-dihydroeudesm-6,12-olide; 2a-hydroxycostic acid; 3-keto-7a-hydroxyeudesm-4-en-6,12-olide (cryptomeridiol); 4-epicryptomeridiol; sphaeranthanolide; 2a-hydroxysphaerantholide; 2a-acetoxysphaerantholide; 2a,7a-dihydroxysphaerantholide; 2a-acetoxy-7a-hydroxysphaerantholide and 2a acetoxy-5a-hydroxyisosphaerantholide or mixtures thereof.
5. The Sphaeranthus indicus derived ingredient as claimed in claims 1 and 2, is obtained from at least one of the plant part selected from leaves, flower heads, stem, root, whole plant or mixtures thereof or is chemically synthesized.
6. The herbal extracts and fractions as claimed in claims 1 to 3, wherein the solvent for extracting or fractionating is selected from the group consisting of Cl to C5 alcohols; CI to C7 hydrocarbons; esters; water and mixtures thereof.
7. The Sphaeranthus indicus extracts or fractions standardized to atleast one frullanolide/eudesmanoid sesquiterpene compound as claimed in claims 1 and 2, wherein the concentration of active compound 7-hydroxyfrullanolide/other frullanolide/eudesmanoid sesquiterpene(s) in the extract(s) and fraction(s) derived from Sphaeranthus indicus either individually or together varies in the range of 0.01% to 99.99%.
8. The compositions as claimed in claims 2 and 3, wherein the concentration of active compounds, a-mangostin and y-mangostin, either individually or jointly in Garcinia mangostana derived extract(s) or fraction(s) varies from 0.01% to
99.99%. 9. The herbal ingredient or composition as claimed in claims 1 to 3, wherein said ingredient or composition formulated into a dietary supplement, food ingredient, beverage, snack or energy drink. 10. The herbal ingredient derived from Sphaeranthus indicus standardized to 7 hydroxyfrullanolide according to claim 1, for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, WO 2012/032544 PCT/IN2011/000612 25 circulatory health, blood vessel health and for better mental health in warm blooded animal. 11. The composition according to claim 2, for enhancing physical activity, physical fitness, mental alertness, enhancing energy levels, stamina levels, circulatory health, blood vessel health and for better mental health in warm blooded animal. 12. A method of enhancing natural energy to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof, wherein the method comprises administering to a subject or mammal or warm blooded animal a therapeutically effective quantity of at least one Sphaeranthus indicus derived herbal ingredient selected from the extracts and fractions standardized to at least one frullanolide/eudesmanoid sesquiterpene compound as claimed in claim 1. 13. A method of enhancing natural energy to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof, wherein the method comprises administering to a subject or mammal or warm blooded animal a therapeutically effective quantity of a composition as claimed in claim 2. 14. A method of enhancing natural energy to provide an onset and steady maintenance of energy and mental alertness in a warm blooded animal or mammal in need thereof, wherein the method comprises administering to a subject or mammal or warm blooded animal a therapeutically effective quantity of a composition as claimed in claim 3.
AU2011300376A 2010-09-11 2011-09-07 Ingredients derived from Sphaeranthus indicus Ceased AU2011300376B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2296CH2010 2010-09-11
IN2296/CHE/2010 2010-09-11
PCT/IN2011/000612 WO2012032544A2 (en) 2010-09-11 2011-09-07 Sphaeranthus indicus derived ingredients and their compositions for enhacing physical performance and energy levels

Publications (2)

Publication Number Publication Date
AU2011300376A1 true AU2011300376A1 (en) 2013-04-04
AU2011300376B2 AU2011300376B2 (en) 2015-12-03

Family

ID=45811029

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011300376A Ceased AU2011300376B2 (en) 2010-09-11 2011-09-07 Ingredients derived from Sphaeranthus indicus

Country Status (7)

Country Link
KR (1) KR20130119424A (en)
CN (1) CN103108556A (en)
AU (1) AU2011300376B2 (en)
CA (1) CA2810793C (en)
MY (1) MY166221A (en)
SG (1) SG188424A1 (en)
WO (1) WO2012032544A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2896990A1 (en) * 2013-01-03 2014-07-10 Laila Nutraceuticals Synergistic dietary supplement compositions for enhancing physical performance and energy levels
US9872871B2 (en) 2013-04-23 2018-01-23 Aarhus Universitet Compositions for use in restoring muscle glycogen and/or muscle mass
CA3023426A1 (en) * 2016-05-21 2017-11-30 Laila Impex Dietary supplements and compositions for enhancing physical performance and energy levels

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002047125A (en) * 2000-05-26 2002-02-12 Shiseido Co Ltd Skin care preparation for inhibiting sebum secretion
US20070196298A1 (en) * 2005-05-31 2007-08-23 Kostick Richard H Cosmetic and dermatological formulations with natural pigments and methods of use
EA014070B1 (en) * 2005-09-30 2010-08-30 Пирамал Лайф Сайнсиз Лимитед Use of a herbal composition for the treatment of inflammatory disorders
AU2010220058B2 (en) * 2009-02-02 2016-02-18 Laila Nutraceuticals Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome

Also Published As

Publication number Publication date
MY166221A (en) 2018-06-22
WO2012032544A2 (en) 2012-03-15
KR20130119424A (en) 2013-10-31
SG188424A1 (en) 2013-04-30
CA2810793C (en) 2023-10-31
CA2810793A1 (en) 2012-03-15
AU2011300376B2 (en) 2015-12-03
WO2012032544A3 (en) 2012-05-10
CN103108556A (en) 2013-05-15

Similar Documents

Publication Publication Date Title
AU2019200802B2 (en) Synergistic dietary supplement compositions for enhancing physical performance
US20050276839A1 (en) Appetite satiation and hydration beverage
WO2008004340A1 (en) Senescence inhibitor
TW200913988A (en) Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient
EP2859896A1 (en) Pharmaceutical compositions for the treatment of muscular disorders
WO2007066642A1 (en) Oral preparation for preventing or improving skin dryness
KR20240004452A (en) 1-Methylxanthine-based bioactive compositions and methods of using the same
AU2011300376B2 (en) Ingredients derived from Sphaeranthus indicus
US20150050260A1 (en) Pyrroloquinoline quinone based compositions and uses
JP6457749B2 (en) VCAM-1 expression inhibitor
JP2002265359A (en) Kainic acid type glutamate receptor-shielding agent, ampa type glutamate receptor shielding agent, brain- protecting agent and food or drink having brain- protecting function
US10105347B2 (en) Sphaeranthus indicus derived ingredients and their compositions for enhancing physical performance and energy levels
US10542989B2 (en) Synergistic dietary supplement compositions for enhancing physical performance and energy levels
JP7460327B2 (en) Oral Compositions
WO2020138026A1 (en) Heat stress alleviation agent
JP2009533433A (en) Compositions containing pyruvate alkyl esters and uses thereof
JP2009023948A (en) Dopamine-inhibiting agent
CN117979971A (en) Bioactive compositions based on 1-methylxanthines and methods of use thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired